SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-C
Report by Issuer of Securities Quoted on NASDAQ
Inter-Dealer Quotation System Filed Pursuant to
Section 13 or 15(d) of the Securities Exchange Act
of 1934 and Rules 13a-17 and 15d-17 Thereunder
ImmunoGen, Inc.
-----------------------------------------------------------------
(Exact name of Issuer as Specified in Charter)
128 Sidney Street, Cambridge, Massachusetts 02139
-----------------------------------------------------------------
(Address of Principal Executive Offices)
(617) 661-9312
-----------------------------------------------------------------
(Issuer's Telephone Number, Including Area Code)
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of five percent or more in the
number of shares outstanding:
1. Title of security ImmunoGen, Inc. Common Stock
--------------------------------------------
2. Number of shares outstanding before the change 12,586,606
----------------
3. Number of shares outstanding after the change 13,656,884
-----------------
4. Effective date of change November 6, 1995
--------------------------------------
5. Method of change:
Specify method (such as merger, acquisition, exchange, distribution, stock
split, reverse split, acquisition of stock for treasury, etc.)
Conversion of Subordinated Convertible Debentures
- ---------------------------------------------------------------------
Give a brief description of transaction Conversion of Subordinated
------------------------
Convertible Debentures issued in previous Regulation S transaction.
- ---------------------------------------------------------------------
II. CHANGE IN NAME OF ISSUER
1. Name prior to change
---------------------------------------------
2. Name after change
------------------------------------------------
3. Effective date of charter amendment changing name
----------------
4. Date of shareholder approval of change, if required
--------------
/S/ Frank J. Pocher, Vice Pres-
Date January 12, 1996 ident and Chief Financial Officer
- -------------------------------- -------------------------------
(Officer's Signature and Title)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-C
Report by Issuer of Securities Quoted on NASDAQ
Inter-Dealer Quotation System Filed Pursuant to
Section 13 or 15(d) of the Securities Exchange Act
of 1934 and Rules 13a-17 and 15d-17 Thereunder
ImmunoGen, Inc.
-----------------------------------------------------------------
(Exact name of Issuer as Specified in Charter)
128 Sidney Street, Cambridge, Massachusetts 02139
-----------------------------------------------------------------
(Address of Principal Executive Offices)
(617) 661-9312
-----------------------------------------------------------------
(Issuer's Telephone Number, Including Area Code)
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of five percent or more in the
number of shares outstanding:
1. Title of security ImmunoGen, Inc. Common Stock
--------------------------------------------
2. Number of shares outstanding before the change 13,656,884
----------------
3. Number of shares outstanding after the change 14,347,799
-----------------
4. Effective date of change November 29, 1995
--------------------------------------
5. Method of change:
Specify method (such as merger, acquisition, exchange, distribution, stock
split, reverse split, acquisition of stock for treasury, etc.)
Conversion of Subordinated Convertible Debentures
- ---------------------------------------------------------------------
Give a brief description of transaction Conversion of Subordinated
------------------------
Convertible Debentures issued in previous Regulation S transaction.
- ---------------------------------------------------------------------
II. CHANGE IN NAME OF ISSUER
1. Name prior to change
---------------------------------------------
2. Name after change
------------------------------------------------
3. Effective date of charter amendment changing name
----------------
4. Date of shareholder approval of change, if required
--------------
/S/ Frank J. Pocher, Vice Pres-
Date January 12, 1996 ident and Chief Financial Officer
- -------------------------------- -------------------------------
(Officer's Signature and Title)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-C
Report by Issuer of Securities Quoted on NASDAQ
Inter-Dealer Quotation System Filed Pursuant to
Section 13 or 15(d) of the Securities Exchange Act
of 1934 and Rules 13a-17 and 15d-17 Thereunder
ImmunoGen, Inc.
-----------------------------------------------------------------
(Exact name of Issuer as Specified in Charter)
128 Sidney Street, Cambridge, Massachusetts 02139
-----------------------------------------------------------------
(Address of Principal Executive Offices)
(617) 661-9312
-----------------------------------------------------------------
(Issuer's Telephone Number, Including Area Code)
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of five percent or more in the
number of shares outstanding:
1. Title of security ImmunoGen, Inc. Common Stock
--------------------------------------------
2. Number of shares outstanding before the change 14,347,799
----------------
3. Number of shares outstanding after the change 15,074,226
-----------------
4. Effective date of change December 13, 1995
--------------------------------------
5. Method of change:
Specify method (such as merger, acquisition, exchange, distribution, stock
split, reverse split, acquisition of stock for treasury, etc.)
Conversion of Subordinated Convertible Debentures
- ---------------------------------------------------------------------
Give a brief description of transaction Conversion of Subordinated
------------------------
Convertible Debentures issued in previous Regulation S transaction.
- ---------------------------------------------------------------------
II. CHANGE IN NAME OF ISSUER
1. Name prior to change
---------------------------------------------
2. Name after change
------------------------------------------------
3. Effective date of charter amendment changing name
----------------
4. Date of shareholder approval of change, if required
--------------
/S/ Frank J. Pocher, Vice Pres-
Date January 12, 1996 ident and Chief Financial Officer
- -------------------------------- -------------------------------
(Officer's Signature and Title)